PureTech Health Launches Seaport Therapeutics with $100M
Ticker: PTCHF · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1782999
| Field | Detail |
|---|---|
| Company | Puretech Health PLC (PTCHF) |
| Form Type | 6-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $100 Million |
| Sentiment | bullish |
Sentiment: bullish
Topics: spin-off, financing, rare-disease, biotech
Related Tickers: PRTC
TL;DR
PureTech Health spins out Seaport Therapeutics, raises $100M for rare disease drugs.
AI Summary
On April 9, 2024, PureTech Health plc announced the launch of Seaport Therapeutics, a new entity focused on developing treatments for rare diseases. The company has secured $100 million in Series A financing to advance its pipeline.
Why It Matters
The creation of Seaport Therapeutics and its significant funding could accelerate the development of novel therapies for rare diseases, potentially impacting patient lives and the biotechnology investment landscape.
Risk Assessment
Risk Level: medium — The success of Seaport Therapeutics is dependent on the efficacy and regulatory approval of its drug candidates, which carries inherent clinical and market risks.
Key Numbers
- $100 million — Series A Financing (Amount raised for Seaport Therapeutics to fund rare disease drug development.)
Key Players & Entities
- PureTech Health plc (company) — Registrant and parent company
- Seaport Therapeutics (company) — Newly launched subsidiary
- $100 million (dollar_amount) — Series A financing for Seaport Therapeutics
- April 9, 2024 (date) — Date of the press release and announcement
FAQ
What is the primary focus of the newly launched Seaport Therapeutics?
Seaport Therapeutics is focused on developing treatments for rare diseases.
How much funding did Seaport Therapeutics secure?
Seaport Therapeutics secured $100 million in Series A financing.
When was the launch of Seaport Therapeutics announced?
The launch was announced on April 9, 2024.
What is the ticker symbol for PureTech Health plc?
The ticker symbols for PureTech Health plc are LSE: PRTC and Nasdaq: PRTC.
What type of report is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 253 words · 1 min read · ~1 pages · Grade level 15.3 · Accepted 2024-04-09 06:30:50
Key Financial Figures
- $100 Million — Tech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces M
Filing Documents
- d798323d6k.htm (6-K) — 9KB
- d798323dex991.htm (EX-99.1) — 37KB
- 0001193125-24-090082.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PURETECH HEALTH PLC Date: April 9, 2024 By: /s/ Bharatt Chowrira Name: Bharatt Chowrira Title: Chief Executive Officer